Recombinant antigens of the porcine circovirus 2 (pcv-2) for vaccine formulations and use thereof

Abstract

The present continuation-in-part of the Application BR 7 10 2013 001893 refers to the obtainment of the viral capsid recombinant antigen of the Porcine circovirus 2 (PCV-2) and modifications thereof, upon expression in prokaryotic system, recovery of virus-like particles (VLPs) and its use in vaccine formulations. The antigens and vaccine formulations can be used in the immunization of animals in control programs of the diseases associated with PCV-2 in conventional swine production systems and represent alternatives to vaccines available on the market.

1 . A recombinant antigen of the porcine circovirus 2 which is the SEQ ID NO: 02. 
     
     
         2 . A recombinant antigen, which comprises the product of the oligomerization of SEQ ID NO: 02 in the form of virus-like particles (VLPs) of the PCV-2. 
     
     
         3 . Vaccine formulations which comprise the antigen as defined in  claim 1 , associated with pharmaceutically acceptable adjuvants. 
     
     
         4 . Uses of the antigen as defined in  claim 1 , which is applied in the production of vaccine compounds. 
     
     
         5 . Use of the vaccine formulations defined in  claim 3 , which is for the control of diseases related to the PCV-2. 
     
     
         6 . Vaccine formulations which comprise the VLPs as defined in  claim 2  associated with pharmaceutically acceptable adjuvants. 
     
     
         7 . Uses of the antigen as defined in  claim 2  which is applied in the production of vaccine compounds. 
     
     
         8 . Use of the vaccine formulations as defined in  claim 6  which is for the control of diseases related to the PCV-2.